Disease Overview：Eosinophilia（EOS）
Eosinophilia refers to an abnormal elevation of eosinophils—granulocytic white blood cells involved in allergic responses, parasitic defense, and certain immune-mediated or neoplastic disorders—in peripheral blood (typically >500/μL) or tissue. When persistent or severe, it may signal underlying conditions such as allergic diseases, helminthic infections, autoimmune disorders (e.g., eosinophilic granulomatosis with polyangiitis), clonal hematologic malignancies (e.g., chronic eosinophilic leukemia, PDGFRA/B-rearranged neoplasms), or idiopathic hypereosinophilic syndrome (HES). Diagnosis requires comprehensive evaluation: complete blood count with differential, peripheral blood smear, bone marrow aspiration and biopsy, cytogenetic and molecular testing (e.g., FISH for PDGFRA rearrangement), and organ-specific imaging to assess end-organ damage (e.g., cardiac MRI, pulmonary function tests). Management is etiology-driven—ranging from corticosteroids and antiparasitic agents to targeted tyrosine kinase inhibitors (e.g., imatinib for PDGFRA+ disease) or biologics like benralizumab.
China offers distinct advantages for eosinophilia management: leading hematology centers—including Peking Union Medical College Hospital and Shanghai Ruijin Hospital—possess deep expertise in rare hematologic disorders, advanced diagnostics (next-generation sequencing, flow cytometry, digital pathology), and access to FDA- and NMPA-approved targeted therapies. Clinical outcomes align with international benchmarks, particularly in PDGFRA+ HES, where imatinib response rates exceed 90%. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality. As a dedicated medical tourism agency, we facilitate seamless care for international patients: vetting JCI-accredited hospitals, coordinating specialist consultations, providing transparent, all-inclusive pricing, and delivering end-to-end support—from visa assistance and translation to post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Eosinophilia (Hematology Department)
I. Non-Surgical / Medication-Based Management
*Target Criteria:* Primary eosinophilia (e.g., idiopathic, drug-induced, parasitic), mild-moderate organ involvement (lung, GI, skin), or as bridge therapy pre-biopsy.
- •First-Line Therapy (Corticosteroids)
- *Cost Breakdown (3-month course, Grade 3A hospital):* - Oral prednisone (5 mg × 100 tabs): $4.20 - CBC + differential × 6: $36.00 - Serum tryptase, IgE, ANA, stool ova/parasite × 3: $128.00 - Chest CT (low-dose): $142.00 - Total estimated: $310.20
- •Second-Line (Targeted Agents)
- Imatinib 100–400 mg/day × 12 months - *Cost Breakdown:* - Generic imatinib (100 mg × 30 tabs): $185.00 - Bone marrow biopsy + cytogenetics/FISH: $395.00 - Quantitative RT-PCR for PDGFRA fusion: $220.00 - Monthly CBC + peripheral blood FISH monitoring × 12: $216.00 - Total estimated: $1,016.00
II. Procedural / Interventional Options
*Eligibility:* Symptomatic hypereosinophilic syndrome (HES) with cardiac fibrosis, severe pulmonary infiltration, or life-threatening thromboembolism unresponsive to ≥8 weeks of steroids/targeted therapy.
- •Therapeutic Leukapheresis
- *Procedure Cost (per session, 3 sessions typical):* $1,280–$1,720 - Pre-op workup (ECG, echocardiogram, coagulation panel, central line placement): $345.00
- •Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
- *Total cost (conditioning + transplant + 100-day inpatient care):* $42,500–$58,000 - Pre-HSCT evaluation (HLA typing, PET-CT, pulmonary function tests, donor screening): $2,860.00
III. Special/Complex Condition Management
- •Cardiac Involvement (Endomyocardial Fibrosis):
- Anticoagulation + heart failure management (3-month regimen): $295.00
- •Neurologic Involvement (eosinophilic meningitis):
Quick Selection Guide
- •<40 years, PDGFRA+, budget < $1,500: Start imatinib — highest efficacy, lowest long-term cost.
- •>65 years, comorbid heart failure, severe symptoms: Leukapheresis + corticosteroids — rapid de-bulking avoids HSCT risks.
- •Moderate disease, limited budget ($300–$500): Steroid monotherapy + rigorous parasitology workup — cost-effective first step.
- •Refractory clonal HES with multi-organ failure: Proceed directly to HSCT evaluation — survival benefit outweighs upfront cost.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Eosinophilia Medical Vacation Packages
Curated transparent all-inclusive packages combining Eosinophilia treatment with China top medical destinations:
